2 results about "Annexin" patented technology

The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such as direct thrombin inhibitors, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, heparin, low molecular weight heparin, argatroban, bivalrudin, hirulog or polyglycans to a patient in need thereof. The invention further relates to the use of dipyridamole for the manufacture of a pharmaceutical composition for treatment of resistance to platelet inhibitors. The invention also relates to a method to diagnose resistance to treatment with platelet inhibitors, said method comprising measurement of the density of binding of Annexin V on platelets.

The invention discloses application of bitter gourd exosomes in radiation heart injury protection, the bitter gourd exosomes and rat myocardial cells (H9C2) are co-cultured and subjected to radiation treatment, MTT experiments show that 5-25 [mu] g/ml of the bitter gourd exosomes can promote the cell viability of the radiated H9C2 myocardial cells, and 10 [mu] g/ml of the bitter gourd exosomes are selected as the use concentration of the bitter gourd exosomes. Under the condition that the bitter gourd exosome is 10 [mu] g/ml, Ki-67 fluorescent staining proves that the bitter gourd exosome can promote proliferation of radiated H9C2 myocardial cells. An Annexin V-PE/7-AAD flow apoptosis experiment and an apoptosis protein cleaved-caspase3 immunoblotting test prove that the bitter gourd exosome can be used for reducing the apoptosis of H9C2 myocardial cells after radiation. Immunofluorescence staining and protein immunoblotting of a DNA damage marker gamma-H2A. X show that the bitter gourd exosome can reduce DNA damage of H9C2 myocardial cells after radiation.